346 related articles for article (PubMed ID: 34263875)
1. [Aducanumab and Alzheimer's disease: a critical reflection.].
Vanacore N; Blasimme A; Canevelli M
Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
[TBL] [Abstract][Full Text] [Related]
2. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
Mukhopadhyay S; Banerjee D
J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
[TBL] [Abstract][Full Text] [Related]
3. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
Vaz M; Silva V; Monteiro C; Silvestre S
Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
[TBL] [Abstract][Full Text] [Related]
4. Aducanumab for Alzheimer's disease: A regulatory perspective.
Nisticò R; Borg JJ
Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
[TBL] [Abstract][Full Text] [Related]
5. Aducanumab: The first targeted Alzheimer's therapy.
Yang P; Sun F
Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
[TBL] [Abstract][Full Text] [Related]
6. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
[TBL] [Abstract][Full Text] [Related]
7. Can we learn lessons from the FDA's approval of aducanumab?
Liu KY; Howard R
Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
[TBL] [Abstract][Full Text] [Related]
8. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
Høilund-Carlsen PF; Alavi A
J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
[TBL] [Abstract][Full Text] [Related]
9. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
Rabinovici GD
N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
[No Abstract] [Full Text] [Related]
10. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
[TBL] [Abstract][Full Text] [Related]
11. Controversial Approval of New Drug to Treat Alzheimer's Disease.
Aschenbrenner DS
Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
[TBL] [Abstract][Full Text] [Related]
12. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
Parums DV
Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
[TBL] [Abstract][Full Text] [Related]
14. Aducanumab: First Approval.
Dhillon S
Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
[TBL] [Abstract][Full Text] [Related]
15. Accelerated Approval of Aducanumab: Where Do We Stand Now?
Barenholtz Levy H
Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
[TBL] [Abstract][Full Text] [Related]
16. Aducanumab: Appropriate Use Recommendations.
Cummings J; Aisen P; Apostolova LG; Atri A; Salloway S; Weiner M
J Prev Alzheimers Dis; 2021; 8(4):398-410. PubMed ID: 34585212
[TBL] [Abstract][Full Text] [Related]
17. Aducanumab for the treatment of Alzheimer's disease.
Tagliapietra M
Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541
[TBL] [Abstract][Full Text] [Related]
18. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro S; Valeri A; Mazzon E
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
[TBL] [Abstract][Full Text] [Related]
19. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
Planche V; Villain N
JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
[No Abstract] [Full Text] [Related]
20. Making the Case for the Accelerated Withdrawal of Aducanumab.
Whitehouse PJ; Saini V
J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]